{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:23:47Z","timestamp":1792301027235,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T00:00:00Z","timestamp":1424044800000},"content-version":"vor","delay-in-days":168,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","krcp-ksn.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Research and Clinical Practice"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.krcp.2014.08.001","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T07:32:26Z","timestamp":1410334346000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Comprehensive approach to diabetic nephropathy"],"prefix":"10.1016","volume":"33","author":[{"given":"Bancha","family":"Satirapoj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon G.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.krcp.2014.08.001_bib1","first-page":"e1","article-title":"United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease & end-stage renal disease in the United States","volume":"59","author":"Collins","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.krcp.2014.08.001_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib3","first-page":"342","article-title":"Genetic factors in the development of diabetic nephropathy","volume":"126","author":"Trevisan","year":"1995","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.semnephrol.2010.01.005","article-title":"Mexican\u2013American admixture mapping analyses for diabetic nephropathy in type 2 diabetes mellitus","volume":"30","author":"Adler","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.2215\/CJN.02560607","article-title":"Genetic factors in diabetic nephropathy","volume":"2","author":"Freedman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib6","first-page":"1119","article-title":"Apolipoprotein E genetic polymorphisms and the development of nephropathy in type 2 diabetes","volume":"96","author":"Satirapoj","year":"2013","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.krcp.2014.08.001_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2337\/db07-0313","article-title":"Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: the Family Investigation of Nephropathy and Diabetes (FIND)","volume":"57","author":"Schelling","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.krcp.2014.08.001_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00439-009-0667-0","article-title":"The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans","volume":"126","author":"McDonough","year":"2009","journal-title":"Hum Genet"},{"key":"10.1016\/j.krcp.2014.08.001_bib9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3109\/0886022X.2013.868319","article-title":"Adiponectin gene polymorphisms and susceptibility to diabetic nephropathy: a meta-analysis","volume":"36","author":"Lin","year":"2014","journal-title":"Ren Fail"},{"key":"10.1016\/j.krcp.2014.08.001_bib10","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.2337\/db09-0641","article-title":"Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy","volume":"58","author":"Pezzolesi","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.krcp.2014.08.001_bib11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2337\/diabetes.55.03.06.db05-1013","article-title":"SLC12A3 (solute carrier family 12 member [sodium\/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy","volume":"55","author":"Kim","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.krcp.2014.08.001_bib12","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2337\/diabetes.54.4.1171","article-title":"Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy","volume":"54","author":"Shimazaki","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.krcp.2014.08.001_bib13","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.2337\/db12-1416","article-title":"From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy","volume":"62","author":"Martini","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.krcp.2014.08.001_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ki.2010.467","article-title":"A genome-wide association study for diabetic nephropathy genes in African Americans","volume":"79","author":"McDonough","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2014.08.001_bib15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/cvr\/cvr300","article-title":"Role of microRNAs in diabetes and its cardiovascular complications","volume":"93","author":"Shantikumar","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.krcp.2014.08.001_bib16","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa021835","article-title":"Regression of microalbuminuria in type 1 diabetes","volume":"348","author":"Perkins","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s001250050983","article-title":"Renoprotection in diabetes: genetic and non-genetic risk factors and treatment","volume":"41","author":"Parving","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.krcp.2014.08.001_bib18","doi-asserted-by":"crossref","unstructured":"Rossing P: Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 49:11\u201319, 2006","DOI":"10.1007\/s00125-005-0077-3"},{"key":"10.1016\/j.krcp.2014.08.001_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Investigators BS: Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib20","first-page":"S228","article-title":"Review on pathophysiology and treatment of diabetic kidney disease","volume":"93","author":"Satirapoj","year":"2010","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.krcp.2014.08.001_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4614-5441-0_11","article-title":"Nephropathy in diabetes","volume":"771","author":"Satirapoj","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.krcp.2014.08.001_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/157339908783502370","article-title":"Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy","volume":"4","author":"Ziyadeh","year":"2008","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.krcp.2014.08.001_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000351989","article-title":"GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy","volume":"38","author":"Heilig","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib24","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/sj.ki.5000033","article-title":"Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton","volume":"69","author":"Dai","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2014.08.001_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1681\/ASN.V95802","article-title":"Effect of glycated proteins on the matrix of glomerular epithelial cells","volume":"9","author":"Singh","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib26","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.diabres.2008.09.017","article-title":"Role of reactive oxygen species in the pathogenesis of diabetic nephropathy","volume":"1","author":"Ha","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.krcp.2014.08.001_bib27","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1172\/JCI66218","article-title":"AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function","volume":"123","author":"Dugan","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.krcp.2014.08.001_bib28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1681\/ASN.2007091048","article-title":"The role of inflammatory cytokines in diabetic nephropathy","volume":"19","author":"Navarro-Gonzalez","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib29","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ki.1992.120","article-title":"Early increased renal procollagen alpha 1(IV) mRNA levels in streptozotocin induced diabetes","volume":"41","author":"Ihm","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2014.08.001_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.freeradbiomed.2013.06.009","article-title":"MicroRNAs: potential mediators and biomarkers of diabetic complications","volume":"64","author":"Kato","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib31","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db11-0082","article-title":"Diabetes complications: the microRNA perspective","volume":"60","author":"Kantharidis","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.krcp.2014.08.001_bib32","doi-asserted-by":"crossref","first-page":"11837","DOI":"10.1074\/jbc.M110.194969","article-title":"MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy","volume":"286","author":"Long","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.krcp.2014.08.001_bib33","doi-asserted-by":"crossref","first-page":"121ra18","DOI":"10.1126\/scitranslmed.3003205","article-title":"MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways","volume":"4","author":"Chau","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.krcp.2014.08.001_bib35","first-page":"41","article-title":"Correlation between clinical diabetic nephropathy and severity of diabetic retinopathy in type 2 diabetic patients","volume":"19","author":"Chuankrekkul","year":"2013","journal-title":"J Nephrol Soc Thai"},{"key":"10.1016\/j.krcp.2014.08.001_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/ajkd.2002.33928","article-title":"Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria?","volume":"40","author":"Adler","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.krcp.2014.08.001_bib38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ki.1986.82","article-title":"Glomerular filtration surface in type I diabetes mellitus","volume":"29","author":"Ellis","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2014.08.001_bib39","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/ki.1995.493","article-title":"Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression","volume":"48","author":"Fioretto","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2014.08.001_bib40","first-page":"553","article-title":"Studies of progressive glomerular sclerosis in the rat","volume":"123","author":"Adler","year":"1986","journal-title":"Am J Pathol"},{"key":"10.1016\/j.krcp.2014.08.001_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.ackd.2011.12.001","article-title":"Novel insights into the relationship between glomerular pathology and progressive kidney disease","volume":"19","author":"Satirapoj","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.krcp.2014.08.001_bib42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-3476(94)70190-3","article-title":"Diabetes Control and Complications Trial","volume":"125","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.krcp.2014.08.001_bib43","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837\u2013853, 1998","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"10.1016\/j.krcp.2014.08.001_bib44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/1056-8727(94)90005-1","article-title":"The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study","volume":"8","author":"Kawazu","year":"1994","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.krcp.2014.08.001_bib45","doi-asserted-by":"crossref","unstructured":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977\u2013986, 1993","DOI":"10.1056\/NEJM199309303291401"},{"key":"10.1016\/j.krcp.2014.08.001_bib46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/ndt\/13.3.651","article-title":"The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy","volume":"13","author":"Mulec","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2014.08.001_bib47","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"Group","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199807093390202","article-title":"Reversal of lesions of diabetic nephropathy after pancreas transplantation","volume":"339","author":"Fioretto","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib49","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.ki.5000153","article-title":"Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients","volume":"69","author":"Fioretto","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2014.08.001_bib50","first-page":"B21","article-title":"Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients","volume":"23","author":"Shichiri","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.krcp.2014.08.001_bib51","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib52","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib53","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib55","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinternmed.2011.2230","article-title":"Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes","volume":"172","author":"Coca","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0889-8529(18)30391-8","article-title":"Hypoglycemia associated with renal failure","volume":"18","author":"Arem","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.krcp.2014.08.001_bib57","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/cc1517","article-title":"Bench-to-bedside review: glucose production from the kidney","volume":"6","author":"Cano","year":"2002","journal-title":"Crit Care"},{"key":"10.1016\/j.krcp.2014.08.001_bib58","first-page":"S87","article-title":"Insulin resistance in dialysis versus non dialysis end stage renal disease patients without diabetes","volume":"94","author":"Satirapoj","year":"2011","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.krcp.2014.08.001_bib59","doi-asserted-by":"crossref","unstructured":"KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49:S12\u2013S154, 2007","DOI":"10.1053\/j.ajkd.2006.12.005"},{"key":"10.1016\/j.krcp.2014.08.001_bib60","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on \u2018KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease\u2019","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2014.08.001_bib61","first-page":"S14","article-title":"Standards of medical care in diabetes\u20142014","volume":"1","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.krcp.2014.08.001_bib62","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1681\/ASN.2006070772","article-title":"Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection","volume":"18","author":"Inaba","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib63","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2215\/CJN.11491210","article-title":"Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients","volume":"6","author":"Freedman","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib64","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1053\/j.ajkd.2009.10.064","article-title":"Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4","volume":"55","author":"Chen","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.krcp.2014.08.001_bib65","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib66","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2004110919","article-title":"Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations","volume":"16","author":"Pohl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/nep.12168","article-title":"Commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease","volume":"19","author":"Roberts","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.krcp.2014.08.001_bib68","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.krcp.2014.08.001_bib69","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.krcp.2014.08.001_bib70","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","article-title":"Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group","volume":"271","author":"Viberti","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.krcp.2014.08.001_bib71","doi-asserted-by":"crossref","unstructured":"Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 39:587\u2013593, 1996","DOI":"10.1007\/BF00403306"},{"key":"10.1016\/j.krcp.2014.08.001_bib72","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib73","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","article-title":"Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data","volume":"134","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib74","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Bergamo Nephrologic Diabetes Complications Trial I: Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials","volume":"151","author":"Bilous","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib76","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib77","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Investigators RT: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib78","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib79","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.krcp.2014.08.001_bib80","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib81","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib82","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib83","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib84","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.krcp.2014.08.001_bib85","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Investigators VN-D: Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib86","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/08037051.2013.812549","article-title":"ESH\/ESC Guidelines for the management of arterial hypertension","volume":"22","author":"Mancia","year":"2013","journal-title":"Blood Press"},{"key":"10.1016\/j.krcp.2014.08.001_bib87","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib88","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib89","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2014.08.001_bib90","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin\u2013angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2014.08.001_bib91","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib92","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2014.08.001_bib93","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000075627","article-title":"Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy","volume":"24","author":"Bolton","year":"2004","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib94","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2215\/CJN.09321209","article-title":"Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria","volume":"5","author":"Adler","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib95","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","article-title":"The effect of ruboxistaurin on nephropathy in type 2 diabetes","volume":"28","author":"Tuttle","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.krcp.2014.08.001_bib96","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1681\/ASN.2011040378","article-title":"Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy","volume":"23","author":"Packham","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib97","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/ndt\/gfm893","article-title":"Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria","volume":"23","author":"Heerspink","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2014.08.001_bib98","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib99","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2006070778","article-title":"Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db\/db mice","volume":"18","author":"Park","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2014.08.001_bib100","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/jpet.111.186866","article-title":"Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats","volume":"340","author":"Liu","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.krcp.2014.08.001_bib101","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1517\/14728214.13.3.447","article-title":"Agents in development for the treatment of diabetic nephropathy","volume":"13","author":"Goh","year":"2008","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["Kidney Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211913214001004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211913214001004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T18:58:32Z","timestamp":1650135512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211913214001004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S2211913214001004"],"URL":"https:\/\/doi.org\/10.1016\/j.krcp.2014.08.001","relation":{},"ISSN":["2211-9132"],"issn-type":[{"value":"2211-9132","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive approach to diabetic nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.krcp.2014.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Korea LLC.","name":"copyright","label":"Copyright"}]}}